Efficacy and Safety Assessment of Intracameral Injection of T2380 in Cataract Surgery

NCT ID: NCT02101359

Last Updated: 2014-11-14

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

609 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-06-30

Study Completion Date

2013-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the efficacy and safety assessment of T2380 for mydriasis and anaesthesia in phacoemulsification cataract surgery versus reference group (topical mydriatics and anaesthetic) 2X246 patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In order to perform pupil size measurements and ocular discomfort assessments at specific times, the surgical procedure was divided into 5 time periods according to the following time points: T1 (just before first incision), T2 (just before viscoelastic injection), T3 (just before capsulorhexis), T4 (just before intraocular lens injection), and T5 (just before cefuroxime injection).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cataract

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

T2380

Topical anaesthetic: Tetracaine was instilled in the eye to be operated before surgery.

At the beginning of surgery, 200 μL of T2380 were administrated intracamerally.

Group Type EXPERIMENTAL

T2380

Intervention Type DRUG

200 microlitres of T2380 will be administrated intracamerally

Tetracaine

Intervention Type DRUG

Two drops of tetracaine were instilled in the eye to be operated 5 minutes and 1 minute before surgery

Mydriatics and anesthetic

Topical anaesthetic: Tetracaine was instilled in the eye to be operated before surgery.

Topical Mydriatic treatments were instilled three times before surgery.

Group Type ACTIVE_COMPARATOR

Mydriatics

Intervention Type DRUG

3 drops of tropicamide and phenylephrine were instilled 30 minutes before surgery. The second and the third instillation of both phenylephrine and tropicamide will be realised respectively within 20 and 10 minutes before surgery.

Tetracaine

Intervention Type DRUG

Two drops of tetracaine were instilled in the eye to be operated 5 minutes and 1 minute before surgery

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

T2380

200 microlitres of T2380 will be administrated intracamerally

Intervention Type DRUG

Mydriatics

3 drops of tropicamide and phenylephrine were instilled 30 minutes before surgery. The second and the third instillation of both phenylephrine and tropicamide will be realised respectively within 20 and 10 minutes before surgery.

Intervention Type DRUG

Tetracaine

Two drops of tetracaine were instilled in the eye to be operated 5 minutes and 1 minute before surgery

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Tropicamide, Phenylpehrine Tetracaine 1%

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed and dated informed consent
* Male or female aged from 40 to 88 years old
* Scheduled to undergo unilateral cataract surgery

Exclusion Criteria

* Combined surgery
* Previous intraocular surgery
Minimum Eligible Age

40 Years

Maximum Eligible Age

88 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Laboratoires Thea

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Joseph COLIN

Role: PRINCIPAL_INVESTIGATOR

Marc LABETOULLE

Role: PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Laboratoires Thea

Clermont-Ferrand, , France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

References

Explore related publications, articles, or registry entries linked to this study.

Labetoulle M, Behndig A, Tassignon MJ, Nuijts R, Mencucci R, Guell JL, Pleyer U, Szaflik J, Rosen P, Berard A, Chiambaretta F, Cochener-Lamard B; Intracameral Mydrane (ICMA), Ethics Group. Safety and efficacy of a standardized intracameral combination of mydriatics and anesthetic for cataract surgery in type-2 diabetic patients. BMC Ophthalmol. 2020 Mar 3;20(1):81. doi: 10.1186/s12886-020-01343-x.

Reference Type DERIVED
PMID: 32126990 (View on PubMed)

Labetoulle M, Findl O, Malecaze F, Alio J, Cochener B, Lobo C, Lazreg S, Hartani D, Colin J, Tassignon MJ, Behndig A; Intracameral Mydrane Study 2 Group. Evaluation of the efficacy and safety of a standardised intracameral combination of mydriatics and anaesthetics for cataract surgery. Br J Ophthalmol. 2016 Jul;100(7):976-985. doi: 10.1136/bjophthalmol-2015-307587. Epub 2015 Nov 3.

Reference Type DERIVED
PMID: 26531052 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LT2380-PIII-05/10

Identifier Type: -

Identifier Source: org_study_id